DeepMind, the Alphabet subsidiary focused on health and AI, announced in a company blog post on Tuesday that its health group will be absorbed by Google. That news comes just days after Google disclosed plans to form a new, centralized health unit at its Silicon Valley, California headquarters led by David Feinberg, a physician and former hospital executive.
Here's what DeepMind pledged about its health biz and relationship with Google. pic.twitter.com/R8bkShFL7X
— malcolmmoore (@MalcolmMoore) November 13, 2018
Julia Powles, a research fellow at NYU Law, tweeted “DeepMind repeatedly, unconditionally promised to never connect people’s intimate, identifiable health data to Google. This isn’t transparency, it’s trust demolition.”
This is TOTALLY unacceptable. DeepMind repeatedly, unconditionally promised to *never* connect people's intimate, identifiable health data to Google. Now it's announced…exactly that. This isn't transparency, it's trust demolition https://t.co/EWM7lxKSET (grabs: Powles & Hodson) pic.twitter.com/3BLQvH3dg1
— Julia Powles (@juliapowles) November 13, 2018
In an interview with CNBC on Tuesday, DeepMind stressed that it still won’t be sharing health information with Google.
A spokesperson said that DeepMind’s work with the NHS will not be impacted. “We’re fully committed to all our NHS partners, and to delivering on our current projects and more,” they said. Under Google Health, the team will continue to work closely with the NHS and “information governance and safety remain our top priorities,” the person explained.
DeepMind also reiterated that patient data would remain under the control of these partners. They also said that the data will continue to be subject to “strict audit and access controls and its processing remains subject to both our contracts and data protection legislation.”
Ultimately, they said, “the move to Google does not affect this.”
DeepMind has been criticized in the past for how its approach to managing health data. In particular, privacy advocates have raised concerns about the issue of consent and whether DeepMind should have asked patients for access to their clinical data.
These questions came up as the company began to work with doctors and nurses to get its Streams app into U.K. hospitals.
To bolster transparency in response to these concerns, DeepMind held regular patient forums in its native U.K. and set up an independent review panel of British physicians, academics and policymakers. That panel could now be disbanded, although no final decision has been made, according to a person familiar with the situation.
Powles, the technology law researcher, remains unconvinced.
“There is nothing more precious and intimate than our personal health information,” she said, referring to DeepMind’s statement as a “diversionary” tactic. “At what point do we say enough is enough?”